Archive for December 13th, 2011

THLD Phase 2 pancreatic data due Feb. ECYT disappoints + CTIC PCYC news

Dec 13, 2011 No Comments by

Threshold Pharmaceuticals, Inc.(NASDAQ: THLD) today announced that it now expects to report the primary analysis of the TH-302 Phase 2 pancreatic trial in mid- to late February of 2012. It completed enrollment of this trial as scheduled in June 2011 with the enrollment of 214 patients. Pharmacyclics, Inc (Nasdaq: PCYC), announced today updated results of a Phase 1b/2 trial of […]

Daily News Read more